FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells

REFERENCES

• Ali, M. M., S. M. Roe, C. K. Vaughan, P. Meyer, B. Panaretou, P. W. Piper, C. Prodromou, and L. H. Pearl. 2006. Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. Nature 440:1013–1017.
   PubMed Web of Science ®Google Scholar
• Barent, R. L., S. C. Nair, D. C. Carr, Y. Ruan, R. A. Rimerman, J. Fulton, Y. Zhang, and D. F. Smith. 1998. Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol. Endocrinol. 12:342–354.
   PubMed Web of Science ®Google Scholar
• Chen, C. D., D. S. Welsbie, C. Tran, S. H. Baek, R. Chen, R. Vessella, M. G. Rosenfeld, and C. L. Sawyers. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10:33–39.
   PubMed Web of Science ®Google Scholar
• Cheung-Flynn, J., V. Prapapanich, M. B. Cox, D. L. Riggs, C. Suarez-Quian, and D. F. Smith. 2005. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol. Endocrinol. 19:1654–1666.
   PubMedGoogle Scholar
• Dehm, S. M., and D. J. Tindall. 2007. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol. 21:2855–2863.
   PubMed Web of Science ®Google Scholar
• Denny, W. B., D. L. Valentine, P. D. Reynolds, D. F. Smith, and J. G. Scammell. 2000. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141:4107–4113.
   PubMed Web of Science ®Google Scholar
• Febbo, P. G., M. Lowenberg, A. R. Thorner, M. Brown, M. Loda, and T. R. Golub. 2005. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol. 173:1772–1777.
   PubMedGoogle Scholar
• Freeman, B. C., and K. R. Yamamoto. 2002. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296:2232–2235.
   PubMed Web of Science ®Google Scholar
• Hubler, T. R., W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell. 2003. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Endocrinology 144:2380–2387.
   PubMedGoogle Scholar
• Johnson, J. L., T. G. Beito, C. J. Krco, and D. O. Toft. 1994. Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes. Mol. Cell. Biol. 14:1956–1963.
   PubMed Web of Science ®Google Scholar
• Kesler, C. T., D. Gioeli, M. R. Conaway, M. J. Weber, and B. M. Paschal. 2007. Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol. Endocrinol. 21:2071–2084.
   PubMedGoogle Scholar
• Klein, K. A., R. E. Reiter, J. Redula, H. Moradi, X. L. Zhu, A. R. Brothman, D. J. Lamb, M. Marcelli, A. Belldegrun, O. N. Witte, and C. L. Sawyers. 1997. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat. Med. 3:402–408.
   PubMed Web of Science ®Google Scholar
• Magee, J. A., L. W. Chang, G. D. Stormo, and J. Milbrandt. 2006. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 147:590–598.
   PubMed Web of Science ®Google Scholar
• McLaughlin, S. H., F. Sobott, Z. P. Yao, W. Zhang, P. R. Nielsen, J. G. Grossmann, E. D. Laue, C. V. Robinson, and S. E. Jackson. 2006. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 356:746–758.
   PubMed Web of Science ®Google Scholar
• Morishima, Y., K. C. Kanelakis, P. J. Murphy, E. R. Lowe, G. J. Jenkins, Y. Osawa, R. K. Sunahara, and W. B. Pratt. 2003. The hsp90 cochaperone p23 is the limiting component of the multiprotein hsp90/hsp70-based chaperone system in vivo where it acts to stabilize the client protein: hsp90 complex. J. Biol. Chem. 278:48754–48763.
   PubMed Web of Science ®Google Scholar
• Mousses, S., L. Bubendorf, U. Wagner, G. Hostetter, J. Kononen, R. Cornelison, N. Goldberger, A. G. Elkahloun, N. Willi, P. Koivisto, W. Ferhle, M. Raffeld, G. Sauter, and O. P. Kallioniemi. 2002. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 62:1256–1260.
   PubMed Web of Science ®Google Scholar
• Nagabhushan, M., C. M. Miller, T. P. Pretlow, J. M. Giaconia, N. L. Edgehouse, S. Schwartz, H. J. Kung, R. W. de Vere White, P. H. Gumerlock, M. I. Resnick, S. B. Amini, and T. G. Pretlow. 1996. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 56:3042–3046.
   PubMed Web of Science ®Google Scholar
• Nair, S. C., R. A. Rimerman, E. J. Toran, S. Chen, V. Prapapanich, R. N. Butts, and D. F. Smith. 1997. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol. Cell. Biol. 17:594–603.
   PubMed Web of Science ®Google Scholar
• Pearl, L. H., and C. Prodromou. 2006. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75:271–294.
   PubMed Web of Science ®Google Scholar
• Pearl, L. H., C. Prodromou, and P. Workman. 2008. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410:439–453.
   PubMed Web of Science ®Google Scholar
• Periyasamy, S., M. Warrier, M. P. Tillekeratne, W. Shou, and E. R. Sanchez. 2007. The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms. Endocrinology 148:4716–4726.
   PubMed Web of Science ®Google Scholar
• Plymate, S. R., M. K. Tennant, S. H. Culp, L. Woodke, M. Marcelli, I. Colman, P. S. Nelson, J. M. Carroll, C. T. J. Roberts, and J. L. Ware. 2004. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 61:276–290.
   PubMedGoogle Scholar
• Powers, M. V., P. A. Clarke, and P. Workman. 2008. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 14:250–262.
   PubMed Web of Science ®Google Scholar
• Pratt, W. B., and D. Toft. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18:306–360.
   PubMed Web of Science ®Google Scholar
• Price, J. T., J. M. W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, and E. W. Thompson. 2005. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res. 65:4929–4938.
   PubMed Web of Science ®Google Scholar
• Ratajczak, T., B. K. Ward, and R. F. Minchin. 2003. Immunophilin chaperones in steroid receptor signalling. Curr. Top. Med. Chem. 3:1348–1357.
   PubMed Web of Science ®Google Scholar
• Riggs, D. L., M. B. Cox, H. L. Tardif, M. Hessling, J. Buchner, and D. F. Smith. 2007. Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid hormone signaling. Mol. Cell. Biol. 27:8658–8669.
   PubMed Web of Science ®Google Scholar
• Riggs, D. L., P. J. Roberts, S. C. Chirillo, J. Cheung-Flynn, V. Prapapanich, T. Ratajczak, R. Gaber, D. Picard, and D. F. Smith. 2003. The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo. EMBO J. 22:1158–1167.
   PubMed Web of Science ®Google Scholar
• Russell, L. C., S. R. Whitt, M. S. Chen, and M. Chinkers. 1999. Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90. J. Biol. Chem. 274:20060–20063.
   PubMedGoogle Scholar
• Saporita, A. J., J. Ai, and Z. Wang. 2007. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509–520.
   PubMed Web of Science ®Google Scholar
• Shank, L. C., and B. M. Paschal. 2005. Nuclear transport of steroid hormone receptors. Crit. Rev. Eukaryot. Gene Expr. 15:49–73.
   PubMedGoogle Scholar
• Smith, D. F., W. P. Sullivan, T. N. Marion, K. Zaitsu, B. Madden, D. J. McCormick, and D. O. Toft. 1993. Identification of a 60-kilodalton stress-related protein, p60, which interacts with hsp90 and hsp70. Mol. Cell. Biol. 13:869–876.
   PubMed Web of Science ®Google Scholar
• Sullivan, W. P., B. A. Owen, and D. O. Toft. 2002. The influence of ATP and p23 on the conformation of hsp90. J. Biol. Chem. 277:45942–45948.
   PubMedGoogle Scholar
• Workman, P. 2004. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. Med. 10:47–51.
   PubMed Web of Science ®Google Scholar
• Yang, C.-S., H.-W. Xin, J. B. Kelley, A. Spencer, D. L. Brautigan, and B. M. Paschal. 2007. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions. Mol. Cell. Biol. 27:3390–3404.
   PubMed Web of Science ®Google Scholar
• Yeh, W. C., T. K. Li, B. E. Bierer, and S. L. McKnight. 1995. Identification and characterization of an immunophilin expressed during the clonal expansion phase of adipocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 92:11081–11085.
   PubMedGoogle Scholar
• Yong, W., Z. Yang, S. Periyasamy, H. Chen, S. Yucel, W. Li, L. Y. Lin, I. M. Wolf, M. J. Cohn, L. S. Baskin, E. R. Sanchez, and W. Shou. 2007. Essential role for cochaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. J. Biol. Chem. 282:5026–5036.
   PubMedGoogle Scholar